Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
55 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Vitiligo - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Vitiligo - Pipeline Review, H1 2015', provides an overview of the Vitiligo's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Vitiligo, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vitiligo and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Vitiligo - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Vitiligo and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Vitiligo products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Vitiligo pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reason to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Vitiligo - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Vitiligo pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Vitiligo Overview 6 Therapeutics Development 7 Pipeline Products for Vitiligo - Overview 7 Pipeline Products for Vitiligo - Comparative Analysis 8 Vitiligo - Therapeutics under Development by Companies 9 Vitiligo - Therapeutics under Investigation by Universities/Institutes 10 Vitiligo - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Vitiligo - Products under Development by Companies 13 Vitiligo - Products under Investigation by Universities/Institutes 14 Vitiligo - Companies Involved in Therapeutics Development 15 Ache Laboratorios Farmaceuticos S/A 15 Biocon Limited 16 Bristol-Myers Squibb Company 17 Clinuvel Pharmaceuticals Limited 18 Reliance Life Sciences Pvt. Ltd. 19 Sun Pharma Advanced Research Company Ltd. 20 Vitiligo - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 abatacept (recombinant) - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 ACH-24 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 afamelanotide - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Gene Therapy to Activate SOX9 for Vitiligo and Melanoma - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 itolizumab - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 ReliDerm-M - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 SUN-0597 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Vitiligo - Recent Pipeline Updates 42 Vitiligo - Dormant Projects 50 Vitiligo - Product Development Milestones 51 Featured News & Press Releases 51 Sep 19, 2014: SCENESSE vitiligo study results published in JAMA Dermatology 51 May 06, 2014: Clinuvel's Phase II vitiligo study commences in Singapore 51 Dec 19, 2012: Clinuvel Pharma Announces Results From Phase IIa Pilot Study Of Scenesse In Vitiligo 52 Mar 02, 2011: Clinuvel Announces FDA Approval For Vitiligo Drug Trial 53 Appendix 54 Methodology 54 Coverage 54 Secondary Research 54 Primary Research 54 Expert Panel Validation 54 Contact Us 54 Disclaimer 55
List of Tables
Number of Products under Development for Vitiligo, H1 2015 7 Number of Products under Development for Vitiligo - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Number of Products under Investigation by Universities/Institutes, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 11 Comparative Analysis by Early Stage Development, H1 2015 12 Products under Development by Companies, H1 2015 13 Products under Investigation by Universities/Institutes, H1 2015 14 Vitiligo - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2015 15 Vitiligo - Pipeline by Biocon Limited, H1 2015 16 Vitiligo - Pipeline by Bristol-Myers Squibb Company, H1 2015 17 Vitiligo - Pipeline by Clinuvel Pharmaceuticals Limited, H1 2015 18 Vitiligo - Pipeline by Reliance Life Sciences Pvt. Ltd., H1 2015 19 Vitiligo - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015 20 Assessment by Monotherapy Products, H1 2015 21 Number of Products by Stage and Target, H1 2015 23 Number of Products by Stage and Mechanism of Action, H1 2015 25 Number of Products by Stage and Route of Administration, H1 2015 27 Number of Products by Stage and Molecule Type, H1 2015 29 Vitiligo Therapeutics - Recent Pipeline Updates, H1 2015 42 Vitiligo - Dormant Projects, H1 2015 50
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.